Common questions about Qbrexza (FAQ)
Q: Is Qbrexza a type of antiperspirant or a different kind of medicine?
A: Qbrexza is classified as a prescription anticholinergic medicine. Its mechanism involves blocking specific nerve signals on the sweat glands. This is different from most traditional antiperspirants, which typically work by creating a plug in the sweat duct to prevent sweat from reaching the skin’s surface.
Q: Can Qbrexza be used on other body parts besides the underarms?
A: According to official product information, Qbrexza is indicated and approved only for use on the underarm areas (axillae). The medicine is indicated solely for this area.
Q: Why is Qbrexza only for underarm sweating?
A: Qbrexza is FDA-approved and indicated solely for the topical treatment of primary axillary hyperhidrosis, which is excessive underarm sweating. The drug’s localized effects and safety profile were studied specifically for this area in adults and children 9 years of age and older.
Q: Does Qbrexza work the same way as Botox for sweating?
A: No. Qbrexza uses glycopyrronium tosylate to block receptors that trigger sweat production. The mechanism of Qbrexza is classified as different from the mechanism of botulinum toxin (Botox), which is another treatment used for excessive sweating.
Q: How quickly does Qbrexza start to feel like it's working?
A: Clinical trials measured the medicine's main efficacy endpoints after 4 weeks of daily use, which is the official assessment timeline. It is intended for ongoing topical treatment.
Q: If I stop using Qbrexza, does the sweating come back right away?
A: The drug is designed for daily, ongoing topical treatment, as its effect is temporary. Based on pharmacology studies for this class of medicine, the reduction in sweating is not permanent, and its effect is expected to dissipate once the medicine is discontinued.
Q: Is Qbrexza safe for long-term use?
A: The safety of Qbrexza has been evaluated in clinical studies that included a long-term open-label extension. Data gathered from these trials supported continuous daily use for a period of up to 48 weeks (nearly one year).
Q: What is the difference between Qbrexza and regular deodorants?
A: Qbrexza is a prescription anticholinergic medicine used to reduce excessive sweat production by interfering with the nerve signals to the sweat glands. Regular deodorants are cosmetic products primarily intended to reduce or mask body odor and do not share the same drug mechanism.
Q: Is there a maximum age limit for using Qbrexza?
A: Official regulatory labeling indicates that the medicine is approved for use in adults and pediatric patients 9 years of age and older. There is no maximum age limit stated in the official product information.
Q: Does Qbrexza interact with common over-the-counter allergy medications?
A: The official product information lists an interaction risk with other medications that have anticholinergic effects. Using these agents together may cause additive side effects like increased dry mouth or blurred vision. Whether an over-the-counter allergy medicine presents this risk depends on its specific active ingredient.
Q: Can I use other skin creams or lotions on the same area as Qbrexza?
A: Regulatory documents state that the area treated with Qbrexza should not be covered with an occlusive dressing (like plastic wrap). Use of other topical products is not addressed in the official product information.
Q: What happens if I accidentally touch my eyes after applying Qbrexza?
A: Accidental exposure to the eyes may cause temporary side effects, such as blurred vision or pupil dilation (mydriasis). Official information advises that if blurred vision occurs, activities requiring clear vision, like driving, should be avoided until the symptom resolves.
Q: Is Qbrexza considered a controlled substance?
A: No. The active ingredient in Qbrexza, glycopyrronium tosylate, is not listed as a controlled substance under the U.S. Controlled Substances Act.
Q: Are there any restrictions on sun exposure while using Qbrexza?
A: The main warning is related to the risk of heat illness (such as heat stroke) when in hot or very warm environmental temperatures. This is because the medicine may reduce sweating in areas other than the underarms, which can impair the body’s ability to cool itself.
Q: Does the medicine in Qbrexza get absorbed into the rest of the body?
A: Studies on the drug’s behavior in the body confirm that systemic absorption does occur after topical application to the underarms. However, the medicine’s chemical structure restricts its absorption, keeping plasma concentrations relatively low.
Q: Do people typically use Qbrexza year-round or just during certain seasons?
A: Qbrexza is indicated for a chronic condition (primary axillary hyperhidrosis) and clinical studies assessed continuous daily use for up to 48 weeks. Therefore, it is generally considered appropriate for ongoing topical treatment as prescribed.
Q: Has Qbrexza been studied in people with other skin conditions?
A: Clinical trials used to assess the drug’s efficacy and safety were focused on patients with primary axillary hyperhidrosis. Patients with certain other medical conditions were excluded from participation in these studies due to the risk of potential worsening by anticholinergic effects.
Q: Is Qbrexza appropriate for people who sweat heavily due to anxiety?
A: The medicine is indicated for primary axillary hyperhidrosis, which is defined as excessive sweating that is not caused by another medical condition or by another medication.
Q: Can I apply Qbrexza right after shaving my underarms?
A: Official product information describes that the medicine should be applied only to clean, dry, intact skin. The label includes a warning not to apply the medicine to areas of broken or irritated skin, which may result from recent shaving.
Q: Does the effectiveness of Qbrexza wear off over time?
A: Clinical studies, including a long-term trial lasting up to 48 weeks, examined continuous use of Qbrexza. These studies indicated that the efficacy was maintained throughout the duration of the trial with continuous daily application.
Q: Can Qbrexza cause side effects that show up days or weeks later?
A: Regulatory information states that some anticholinergic side effects, such as urinary retention or constipation, may develop or worsen after initiating or continuing treatment.
Q: Why is there a specific instruction about washing my hands after using the cloth?
A: Handwashing with soap and water is part of the application procedure and is intended to be done immediately after application as a safety measure. This is to reduce the risk of accidentally transferring the medicine from the hands to the eyes, which can cause temporary blurred vision or pupil dilation.
Q: Does Qbrexza contain aluminum?
A: No. The active ingredient in Qbrexza is glycopyrronium tosylate, which is an anticholinergic compound. The drug's composition does not include aluminum.
Q: Why is Qbrexza only available as a prescription?
A: Regulatory documents state that Qbrexza requires a prescription primarily due to the potential for certain serious anticholinergic effects, such as the risk of urinary retention and impaired body temperature control, which require professional guidance and monitoring.
Q: How often do people using Qbrexza experience blurred vision?
A: In clinical trials, blurred vision was reported with some frequency. The official product information cites an incidence for the blurring of vision and mydriasis (pupil dilation) of approximately 7% for each symptom.
Q: What type of doctor usually prescribes Qbrexza?
A: As a prescription medicine for a specific dermatological condition, Qbrexza may be prescribed by dermatologists or primary care providers. Any licensed healthcare provider who treats chronic sweating disorders can prescribe the medication.
